ClinicalTrials.Veeva

Menu

Prognosis of Early-onset Anorexia Nervosa (AM2P)

A

Assistance Publique - Hôpitaux de Paris

Status

Enrolling

Conditions

Anorexia Nervosa

Study type

Observational

Funder types

Other

Identifiers

NCT07311356
APHP250984
2025-A01680-49 (Other Identifier)

Details and patient eligibility

About

The AM2P study aims to evaluate the long-term prognosis and quality of life of patients with early-onset anorexia nervosa, assessed 4 to 9 years after hospitalization. Prognosis will be determined using a composite outcome measure based on questionnaire responses and health indicators, including body mass index (BMI). In addition, the study will examine the patients' overall physical condition both at the time of assessment and during the interval between their last hospitalization and the present evaluation.

Full description

This study includes all patients who were hospitalized at Robert Debré Hospital in Paris between 2016 and 2021 for early-onset anorexia nervosa. During follow-up interviews, participants will complete a standardized set of questionnaires assessing their mental and physical health (EDE-Q, PHQ-9, MSI-BPD, GAD-7, and SF-12). The primary outcome is the evaluation of the severity of the eating disorder, measured with the EDE-Q. Secondary outcomes will be derived from the additional questionnaires and will include body mass index (BMI), menstrual status, follow-up data, general well-being, impact of the eating disorder, hospital readmission, suicide attempts, depressive symptoms, borderline personality traits, anxiety, quality of life, educational attainment, occupational status, and treatments received. We hypothesize that approximately 50% of patients will achieve remission three years after hospitalization.

Enrollment

140 estimated patients

Sex

All

Ages

Under 30 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • First full hospitalization in the eating disorders unit (EDU) at Robert Debré Hospital and diagnosis of AMP from 2016 to 2021
  • No objection from the minor to the study
  • Proficiency and understanding of the French language
  • Access to digital technology (computer, smartphone, tablet, etc.)

Exclusion criteria

  • Primary diagnosis of ARFID, other unspecified eating disorder

Trial design

140 participants in 1 patient group

Cohorte AM2P
Description:
Completion of quality of life questionnaire, clinic

Trial contacts and locations

1

Loading...

Central trial contact

Anael AYROLLES, MD; Coline STORDEUR, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems